Daniel Bensen - Mar 27, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Mar 27, 2023
Transactions value $
-$209,478
Form type
4
Date filed
3/29/2023, 07:53 PM
Previous filing
Mar 23, 2023
Next filing
Apr 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $4.91K +8.05K +1.52% $0.61* 536K Mar 27, 2023 Direct
transaction TYRA Common Stock Sale -$129K -8.05K -1.5% $16.00 528K Mar 27, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $2.04K +3.35K +0.63% $0.61* 531K Mar 28, 2023 Direct
transaction TYRA Common Stock Sale -$53.5K -3.35K -0.63% $16.00 528K Mar 28, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $1.33K +2.19K +0.41% $0.61* 530K Mar 29, 2023 Direct
transaction TYRA Common Stock Sale -$35.5K -2.19K -0.41% $16.21 528K Mar 29, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -8.05K -3.25% $0.00 239K Mar 27, 2023 Common Stock 8.05K $0.61 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -3.35K -1.4% $0.00 236K Mar 28, 2023 Common Stock 3.35K $0.61 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2.19K -0.93% $0.00 234K Mar 29, 2023 Common Stock 2.19K $0.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.